Solids can either be arranged in a repeating three-dimensional crystalline structure or in an amorphous state where there is no regular pattern. The crystalline form affects the solubility and the dissolution rate of a solid, thus the form influences the efficacy of the drug and must be carefully controlled during the manufacturing process. AstraZeneca is seeking collaboration partners who can identify novel technologies or approaches for the large-scale manufacture of a highly complex crystalline pharmaceutical material.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.
To ensure a high level of purity and thermodynamic stability, many active pharmaceutical ingredients are manufactured in a crystalline state. AstraZeneca is looking for a collaborator with whom to develop novel isolation techniques for producing this crystalline pharmaceutical material with limited chemical stability in suitable solvent systems. Successful proposals should focus on novel approaches that will yield the desired crystalline form and particle size (> 20 µm) in a cost-effective manner, under conditions that conform to the Good Manufacturing Practice Regulations at a large-scale in a controlled process.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (maximum of 10 pages, including supporting non-confidential information and contact details) to be evaluated by AstraZeneca with a goal of establishing a collaborative partnership. Upon completion of the evaluation, AstraZeneca may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.
[NOTE: Only proposals from Solvers who have the ability to work as a collaboration partner will be considered.]
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on April 16, 2018.
Late submissions will not be considered.
ABOUT THE SEEKER
AstraZeneca is a global, science-led, biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca also is selectively active in the areas of autoimmunity, neuroscience and infection. As an innovation-driven research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.